Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spectral MedicalSTU:SD4 +1.23%14 Median PS Value is €0.27 as of Jul. 15, 2026, which is 100% below its 10-year median of 2.11. GuruFocus rates STU:SD4 with a GF Score™ of 14/100 and a GF Value™ of €0.56 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 88 Medical Diagnostics & Research companies, Spectral Medical ranks worse than 97.73% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Spectral Medical's Median PS Value or its related term are showing as below:
STU:SD4'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 1.06 Med: 2.11 Max: 12.38
Current: 3.06
During the past 13 years, the highest Price to Median PS Value of Spectral Medical was 12.38. The lowest was 1.06. And the median was 2.11.
STU:SD4's Price-to-Median-PS-Value is ranked worse than 97.73% of 88
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.885
vs STU:SD4: 3.06
Spectral Medical (STU:SD4) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Spectral Medical's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.825
/
0.27
=
3.06
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral Medical Median PS Value Related Terms
Spectral Medical Median PS Value Historical Data
* Premium members only.
The historical data trend for Spectral Medical's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:SD4 vs TMO, DHR, IDXX: Median PS Value Comparison
For the Diagnostics & Research subindustry, Spectral Medical's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spectral Medical Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Spectral Medical's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Spectral Medical's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 45.
Spectral Medical's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.006.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Spectral Medical (STU:SD4) has a Median PS Value of €0.27 as of Jul. 15, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Spectral Medical and its competitors. This is 87% below median its historical median of 2.11. Over the past decade, Spectral Medical's Median PS Value has ranged from 1.06 to 12.38. According to the industry distribution chart, Spectral Medical ranks #86 out of 88 companies in the Medical Diagnostics & Research industry, placing it in the top 97.7%.
Is Spectral Medical's Median PS Value too high?
Spectral Medical's current Median PS Value of €0.27 is 87% below median its 10-year median of 2.11. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 12.38. Based on the distribution chart, Spectral Medical ranks #86 out of 88 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Spectral Medical has a GF Score™ of 14/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spectral Medical's Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Spectral Medical ranks #86 out of 88 companies for Median PS Value. This places Spectral Medical in the lower half of its industry. The industry median Median PS Value is 0.89. Historically, Spectral Medical's own Median PS Value has ranged from 1.06 to 12.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.89, based on 88 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Spectral Medical and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spectral Medical's current Median PS Value is €0.27, which is 87% below median its own 10-year median of 2.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spectral Medical stock overvalued right now?
Based on GuruFocus' analysis, Spectral Medical (STU:SD4) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.56, compared to a current price of €0.83 — trading 47.3% above its estimated fair value. The current Median PS Value is €0.27, which is 87% below median its 10-year median of 2.11. Spectral Medical's overall GF Score™ is 14/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Spectral Medical (STU:SD4), the current Median PS Value is €0.27 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spectral Medical (STU:SD4) Overvalued in 2026?
Based on GuruFocus' analysis, Spectral Medical stock appears to be overvalued.
The current stock price of €0.83 is trading 47.3% above its estimated GF Value™ of €0.56.
GuruFocus considers Spectral Medical to be Significantly Overvalued.
Key valuation signals for STU:SD4:
Median PS Value: €0.27 (87% below median its 10-year median of 2.11)
GF Value™: €0.56 vs. price of €0.83 (47.3% above fair value)
No single metric tells the full story. See the STU:SD4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spectral Medical Inc is focused on the development and commercialization of a treatment for septic shock utilizing its endotoxin activity assay (EAA) diagnostic and the Toraymyxin therapeutic. The company also manufactures and sells proprietary reagents. The product line of the company consists of proprietary biochemical, EAA, and instrumentation. Its products include an endotoxin activity assay, a rapid in-vitro diagnostic test used to measure endotoxin levels in blood, and a polymyxin B hemoperfusion device designed to remove endotoxin from the bloodstream. The company's proprietary reagents include recombinant proteins, antibodies, and calibrators used in research and diagnostic applications.
14GF Score
Get the complete analysis for STU:SD4
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:SD4 has been successfully added to your 
